SpringLeaf Therapeutics is creating innovative therapeutic modalities to address serious disease and elevate the quality of care for patients. SpringLeaf’s technology is based on the convergence of materials science and medicine  and is designed to enable and differentiate therapeutics. SpringLeaf was founded based on breakthrough science at MIT and is backed by leading investors including SR One, Flybridge Capital Partners and North Bridge Venture Partners.